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ABSTRACT
Introduction: Treatment options for metastatic prostate cancer are limited and cures are rare.
In other cancers immunotherapy has shown remarkable efficacy in certain patient subsets
particularly when combined with other treatment modalities. Our previous work showed that
combining radiation and vaccine therapy slows the growth of syngeneic prostate cancer in
mice more effectively than single modality treatment arms. Here we tested the hypothesis that
addition of immune checkpoint inhibitors targeting the PD1/PD-L1 axis further improves
efficacy of the dual radiation/vaccine treatment.

RESULTS

Tumor growth inhibition by trimodal radio-immunotherapy targeting the PD1 immune
checkpoints upregulated by dual therapy
A

Concurrent administration schedule of ADXS-PSA vaccine and RT effectively inhibits
growth of TPSA23 cells transplanted to syngeneic C57BL/6 mice
A
B

Methods: Mice were injected with tumor cells expressing human prostate specific antigen
(TPSA-23). The mice were divided into six groups. One group received no therapy. One group
received vaccine and radiation alone. The other four groups received radiation, vaccine, and
either a PD-1 or PD-L1 inhibitory antibody or its corresponding isotype control. Tumors were
measured twice weekly, growth curves generated, and results were analyzed using a 2-way
ANOVA test.

B

Results: Mice receiving radiation and vaccine therapy demonstrated delayed tumor growth as
compared to untreated mice. Addition of the anti-PD- 1 antibody was significantly (p=0.0005)
more effective than dual treatment in delaying tumor growth when compared to
corresponding isotype controls at early time points. However, overall survival was not
significantly improved by either antibody targeting the PD1/PD-L1 axis beyond the growth
inhibition achieved by the radiation/vaccine combination.
Conclusions: Our results suggest that PD1 checkpoint blockade may have utility when added to
radiation/vaccine immunotherapy in a murine prostate cancer model. The molecular correlates
of these effects are yet to be determined.

A. Schedules for dual treatment (radiation and PSA vaccine) sequenced differently. B. Concurrent
administration of radiation and vaccination most effectively reduces tumor volume measured at
day 25 after tumor cell inoculation. Concurrent dual treatment served as a baseline for the
treatment schedule used in triple combination therapy experiments (RT/PSA vaccine/PD-1/PD-L1
inhibitors). These results also establish the superiority of dual therapy over single treatment
modalities.

BACKGROUND
ADXS-PSA is an attenuated Listeria monocytogenes (Lm) strain genetically engineered to secrete a fusion
protein composed of human PSA and a truncated nonhemolytic form of listeriolysin O LLO (tLLO-PSA).
Lm is taken up by antigen presenting cells (APC) and
secretes LLO to escape the phagolysosome and
enter the cytosol. The tLLO-PSA fusion protein is
processed into peptides, which are subsequently
presented to T cells via MHC molecules.

A. Schedule of treatment for triple combination therapy experiment. TPSA23 tumors were treated
with PSA vaccine on days 10, 17, and 21 and irradiated (10 Gy) on day 12. Additionally, an αPD-1
(RMP1-14) or an αPD-L1 antibody (10F.9G2), or an appropriate isotype control, were administered ip
on day 20, 23, and 26. B. Spaghetti plots show tumor volume over time. Each line represents tumor
volume progression in one mouse. Trimodal radio-immunotherapy including αPD-1 was more
effective than dual combination therapy in inhibiting tumor growth at early time points, although all
tumors eventually developed resistance and recurred.

Survival of mice treated with dual or triple immunotherapy
Concurrent administration of ADXS-PSA vaccine and RT enhances infiltration of T
lymphocytes in tumors and induces PD1 expression in a subset of those T cells

A

Kaplan-Meier representation of survival of mice in different treatment groups. Mice
were sacrificed when surrogate endpoints were reached. Despite early tumor growth
inhibition, triple treatment did not extend survival when compared to dual therapy.

B

CONCLUSIONS
Immuno-radiotherapy utilizes radiation, a common cancer
therapeutic modality, to induce immunogenic cell death
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ADXS-PSA and RT combination therapy has shown efficacy in mice bearing TRAMPC1 prostate tumor
cells engineered to express human PSA (TPSA23).
Hypothesis: Adding checkpoint inhibitors targeting the PD1/PD-L1 axis enhances therapeutic
efficacy of dual RT/ADXS-PSA therapy.

A. Detection of intratumoral CD4+ and CD8+ T cells in tumors by immunofluorescence microscopy.
Representative images are shown from tumors in mice receiving no treatment, radiation alone,
vaccine alone, or dual radiation and vaccine therapy. Radiation therapy combined with vaccine
cooperatively increased intratumoral infiltration with CD4+ and CD8+ T cells. B. Quantitative analysis
of intratumoral T cell infiltrates as determined by FACS analysis. Vaccine and dual RT plus vaccine
treatment increased abundance of T cells coexpressing PD1 and CD137 on day 20. These cells were
also found at high frequency in tumors recurring at day 38 regardless of treatment. These results
supported the rationale to target the PD-1 axis following dual treatment (starting on day 20).

•

Combination therapy with sub-therapeutic doses of RT and PSA vaccine cooperatively reduces
tumor burden compared to single modality treatments, confirming prior observations.
Survival improved for all groups receiving dual therapy when compared to controls.
Concurrent administration of vaccine and radiation provides the greatest reduction in tumor
growth.
Therapeutic effects are associated with increased T cell content of tumors.
Expression of the immune checkpoint receptor PD-1 is increased in recurring tumors.
Targeting either PD1 or its ligand PD-L1 transiently enhances efficacy of the dual vaccine/RT
combination. This effect is statistically significant for anti-PD1.
However, targeting PD1 or its ligand PD-L1 does not significantly increase overall survival.
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